Protein Degrader Service
PROTAC & targeted protein degradation — computational design by ICDMO, synthesis and GMP through qualified partners
Overview
Conventional small-molecule inhibitors occupy an enzyme's active site or binding pocket to block its activity — a mechanism that is effective yet fundamentally constrained. Many disease-driving proteins lack accessible catalytic sites, adopt resistance-conferring mutations, or require continuous high drug exposure to sustain target suppression. These limitations have driven the emergence of targeted protein degradation (TPD) as a transformative therapeutic modality.
Proteolysis-Targeting Chimeras (PROTACs) — the leading class of protein degraders — are heterobifunctional small molecules that recruit an E3 ubiquitin ligase into proximity with a target protein, triggering its ubiquitination and subsequent destruction by the 26S proteasome. Unlike occupancy-based inhibitors, a single PROTAC molecule acts catalytically: after delivering the target for degradation it is released to engage additional copies, achieving deep and sustained target depletion at sub-stoichiometric concentrations.
ICDMO provides fully integrated protein degrader development services spanning molecular design, hit identification, medicinal chemistry optimisation, biological evaluation, DMPK profiling, and GMP-grade manufacturing — enabling clients to progress from concept to clinical candidate with a single, accountable partner.
What Is a Protein Degrader?
A protein degrader (PROTAC) is a bifunctional small molecule engineered to induce the selective destruction of a target protein through the cell's own ubiquitin–proteasome system (UPS). Each degrader molecule incorporates three functional elements:
01
Target Protein Ligand (Warhead)
Binds the protein of interest (POI) with high affinity and selectivity, directing the degrader complex to the intended molecular target.
02
E3 Ligase Ligand
Recruits an E3 ubiquitin ligase (commonly CRBN, VHL, MDM2, or IAP) to the ternary complex, positioning it to ubiquitinate the target protein.
03
Linker
A chemical moiety connecting the two binding elements. Linker length, rigidity, and physicochemistry determine ternary complex geometry, cooperativity, and cellular permeability.
Mechanism of Action
The degrader simultaneously engages the target protein and an E3 ligase to assemble a ternary complex. The ligase catalyses polyubiquitination of the target, tagging it for recognition by the 26S proteasome. After proteolytic destruction of the target, the degrader is released intact and recycles to drive additional rounds of degradation. This catalytic "one-to-many" stoichiometry distinguishes PROTACs mechanistically from all conventional inhibitor classes and underpins their superior efficacy at low doses.
Advantages of Protein Degraders
Expanding Druggable Targets
Protein degraders can address proteins previously considered undruggable—including scaffold proteins and transcription factors—without requiring permanent occupancy of a catalytic active site.
Catalytic Efficiency
A single degrader molecule can sequentially eliminate multiple copies of the target protein, reducing required drug concentrations and the probability of off-target engagement.
Overcoming Drug Resistance
By eliminating the target protein entirely, degraders bypass resistance arising from point mutations in active sites or ATP-binding pockets that diminish conventional inhibitor binding.
Clearance of Toxic Aggregates
Degraders remove dysfunctional or aggregated proteins at the source, offering particular promise in neurodegeneration—including Alzheimer's and Parkinson's disease models.
Selective E3 Ligase Recruitment
Rational selection of E3 ligase partners (VHL, CRBN, MDM2, IAP) enables tissue- and context-selective degradation, improving therapeutic index and reducing systemic toxicity.
Low Effective Dose
Owing to their catalytic mechanism of action, degraders achieve robust target elimination at doses substantially lower than those required for stoichiometric inhibitors.
Clinical Pipeline & Key Milestones
Protein degrader technology was pioneered by Crews and Deshaies in 2001. Early first-generation PROTACs were limited by poor cell permeability and modest pharmacokinetics; second-generation molecules incorporating drug-like CRBN and VHL ligands have since entered clinical trials across oncology and immunology. The table below summarises representative clinical-stage degraders as of 2024.
| Company | Degrader | Indication | E3 Ligase |
|---|---|---|---|
| Arvinas | ARV-110 | Prostate cancer | CRBN |
| Arvinas / Pfizer | ARV-471 | Breast cancer | CRBN |
| Accutar Biotech | AC682 | Breast cancer | CRBN |
| Arvinas | ARV-766 | Prostate cancer | CRBN |
| Bristol Myers Squibb | CC-94676 | Prostate cancer | CRBN |
| Dialectic Therapeutics | DT2216 | Liquid & solid tumors | VHL |
| Foghorn Therapeutics | FHD-609 | Synovial sarcoma | CRBN |
| Kymera / Sanofi | KT-474 | Autoimmune diseases | IRAK4 |
| Kymera | KT-413 | Autoimmune diseases | IRAK4 |
| Kymera | KT-333 | Liquid & solid tumors | STAT3 |
| Nurix Therapeutics | NX-2127 | Liquid & solid tumors | CRBN |
| Nurix Therapeutics | NX-5948 | Liquid & solid tumors | CRBN |
| C4 Therapeutics | CFT-8634 | B-cell malignancies | CRBN |
| C4 Therapeutics | CFT-8919 | B-cell malignancies / autoimmune | CRBN |
| C4 Therapeutics | CFT7455 | Synovial sarcoma | CRBN |
| Cullgen | CG001419 | Cancer & other indications | CRBN |
Challenges in Protein Degrader Development
⚠ Complex Drug Properties
Most PROTACs exceed Lipinski's "Rule of Five" in molecular weight and lipophilicity, creating challenges for oral bioavailability, membrane permeability, and metabolic stability. Macrocyclisation and prodrug strategies are actively explored to address these liabilities.
⚠ E3 Ligase Resistance
Genomic alterations in E3 ligase components — such as reduced CRBN or CUL2 expression — have been identified as resistance mechanisms in clinical samples. Expanding the repertoire of utilised ligases beyond CRBN and VHL is a key strategy for next-generation degraders.
⚠ Hook Effect Management
At high degrader concentrations, simultaneous saturation of the target protein and E3 ligase yields binary complexes rather than productive ternary complexes, reducing degradation efficiency. Careful dose–response profiling (DC50/Dmax) and linker optimisation are required to manage this effect.
⚠ Target Selection Breadth
Despite the theoretical ability of PROTACs to address undruggable proteins, the majority of current clinical programmes target established oncoproteins with known ligands. Advancing truly novel targets requires identification of initial binders, often via fragment screening, covalent chemistry, or DEL approaches.
ICDMO's Protein Degrader Development Services
ICDMO delivers end-to-end solutions for protein degrader programmes — integrating computational design, organic synthesis, biological evaluation, and GMP manufacturing into a seamless, accountable service model. Our multidisciplinary team works in close partnership with clients to accelerate progress from initial concept through to IND-enabling candidate selection.
Platform Capabilities
Detailed Services
Project & Data Management
Advancing a protein degrader programme requires more than scientific expertise — it demands rigorous project coordination, clear communication, and data-driven decision-making at every stage. ICDMO is committed to the following principles on every engagement:
Integrated Cross-Functional Collaboration
Chemistry, biology, and DMPK/ADME activities are planned and executed in alignment, eliminating sequential bottlenecks and enabling early learnings to inform parallel workstreams.
Proactive Milestone Management
Clear go/no-go criteria, early risk flags, and contingency plans ensure that projects adapt to emerging data without losing momentum or exceeding budget.
Transparent & Frequent Communication
Regular data packages, project calls, and an online data portal give clients full visibility into progress, analytical results, and upcoming deliverables at all times.
Data-Driven Candidate Prioritisation
Integrated SAR, DMPK, and degradation data are compiled in structured dashboards that support objective candidate scoring and resource allocation at every decision point.
What We Need From You
▸Target structure with any known binder and its binding mode, or the sequence if modelling is needed
▸Cell system and tissue of interest, which bear on E3 ligase expression and selection
▸Existing degrader data: compounds made, degradation results, hook effect observations, resistance findings
▸Chemistry available in house or through your synthesis partner, including linker chemistry precedent
▸Whether oral exposure is required, since it heavily constrains the accessible design space
How the Work Is Performed
▸Target degradability assessment from lysine accessibility, turnover and surface compatibility
▸E3 ligase shortlisting on expression, structural complementarity and available chemistry
▸Warhead exit vector analysis and, where no suitable binder exists, virtual screening for one
▸Linker enumeration across attachment points, lengths and rigidity with ternary complex modelling
▸Cooperativity assessment from interface analysis and simulation-based stability of the ternary arrangement
▸Property and permeability prediction with models appropriate to beyond-rule-of-five chemistry
What You Receive
▸Degradability assessment with a clear recommendation on whether to proceed
▸Ranked degrader designs with ternary complex models and the linker rationale for each
▸Cooperativity and interface analysis per design
▸Predicted physicochemical and permeability profiles with the risk stated
▸A synthesis and testing order in which each compound tests a distinct hypothesis
Interpretation and Limitations
Modelling identifies designs that are geometrically and energetically plausible and removes those that are not. It does not predict DC50, Dmax or the hook effect, which depend on ubiquitination efficiency, cellular context and proteasome processing. Degrader campaigns remain empirical: the purpose of the computational work is to make the first synthesis round systematic rather than to replace it. Synthesis and biological testing are performed by your team or a qualified partner.
Questions We Are Asked Before Scoping
Can you tell us whether our target is degradable?
We can assess the structural and biological factors that make degradation plausible, and identify targets that clearly lack them. Final confirmation is empirical, and we say so before the project starts.
How many linker variants should we make?
Most first rounds run to fifteen or thirty. Ranking makes that round informative; it does not shrink it to three, because degrader activity is not predictable at that resolution.
CRBN, VHL or something else?
It depends on tissue expression, surface complementarity with your target, resistance liabilities and the chemistry you can access. We shortlist and model rather than defaulting to the two most common ligases.
What Published Work Reports
The results below were published by independent groups and are cited to show what these computational approaches have achieved in the literature. They are not ICDMO project results, and outcomes vary substantially between targets, datasets and programmes. We do not promise comparable results for any particular project.
AI-designed molecules have now produced clinical-stage compounds
A compound designed by generative methods against an AI-nominated target completed a randomised Phase 2a trial in idiopathic pulmonary fibrosis, reporting a mean forced vital capacity change of +98.4 mL in the 60 mg once-daily arm against −20.3 mL for placebo over 12 weeks in 71 patients. The result shows that generative design can produce molecules that survive to clinical testing; it does not show that any individual generated series will.
Nature Medicine, 2025 ↗ICDMO brings together computational chemists, medicinal chemists, cell biologists, and process development scientists in a unified team dedicated to delivering high-quality protein degrader candidates on time and on budget. Our flexible engagement model supports both milestone-based collaborations and fully outsourced programmes.
Ready to advance your protein degrader project? Contact our scientific team to discuss your programme, review our compound libraries, or request a no-obligation quote.